Carregando...
Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts
mTOR is a rational target in renal cell carcinoma (RCC) because of its role in disease progression. However, the effects of temsirolimus, the only first-generation mTOR inhibitor approved by the FDA for first-line treatment of metastatic RCC, on tumor reduction and progression-free survival are mini...
Na minha lista:
| Publicado no: | Int J Cancer |
|---|---|
| Principais autores: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4365782/ https://ncbi.nlm.nih.gov/pubmed/24243565 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.28579 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|